Insulet price target raised to $245 from $238 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Insulet to $245 from $238 and keeps an Equal Weight rating on the shares. The macro backdrop remains challenging for medical supplies and devices and the timing for improvements in inflationary pressures, supply chain issues and hospital staffing challenges is uncertain, Miksic tells investors in a research note. However, the analyst remains "generally constructive" on the sector, seeing improving volume trends, stable staffing challenges, and "potentially stabilizing" supply chain and inflationary cost trends. He continues to favor names with operating leverage or "discontinuous and favorable tailwinds, as they are generally better positioned to weather higher input costs."